A recent study demonstrated widespread substitution of analog for human insulin and rising out-of-pocket costs in privately insured people with type 2 diabetes in the United States.
1 Medicaid reimbursements have increased for both human insulin and more costly analog insulins.
2 Although studies have described per-person changes in excess medical spending of US adults with diabetes on prescription medications,
3 they have not reported trends in expenditures for different classes of antihyperglycemic medications that simultaneously consider changes in use and price.